Purple Biotech Ltd.
Develops cancer therapies to overcome tumor immune evasion and drug resistance.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Manufacturing
Description
Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-01 16:14 |
o Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Vir…
|
English | 36.8 KB | ||
| 2025-03-29 23:22 |
6K:Purple Biotech Announces Three Posters Accepted for Presentation at the 2025…
|
English | 167.7 KB | ||
| 2025-03-29 23:22 |
6K:Purple Biotech Announces Three Posters Accepted for Presentation at the 2025…
|
English | 36.7 KB | ||
| 2025-03-19 01:53 |
6K:Purple Biotech Corporate Presentation March 2025
|
English | 30.0 MB | ||
| 2025-03-19 01:53 |
6K:Purple Biotech Corporate Presentation March 2025
|
English | 36.6 KB | ||
| 2025-03-11 00:06 |
Annual report for 2024 on form 20F
|
Hebrew (modern) | 10.7 MB | ||
| 2025-03-11 00:06 |
Annual report for 2024 on form 20F
|
English | 36.7 KB | ||
| 2025-03-10 16:43 |
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
|
English | 330.8 KB | ||
| 2025-03-10 16:43 |
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
|
English | 36.8 KB | ||
| 2025-03-10 16:21 |
The company's financial results for 2024 were reported abroad
|
Hebrew (modern) | 61.6 KB | ||
| 2025-03-05 15:14 |
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antib…
|
English | 221.3 KB | ||
| 2025-03-05 15:14 |
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antib…
|
English | 36.7 KB | ||
| 2025-03-02 00:23 |
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4…
|
English | 83.7 KB | ||
| 2025-03-02 00:23 |
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4…
|
English | 524.3 KB | ||
| 2025-03-02 00:23 |
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4…
|
English | 121.1 KB |
Automate Your Workflow. Get a real-time feed of all Purple Biotech Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Purple Biotech Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Purple Biotech Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
